GenePOC Instrument, Assays Get CE Mark | GenomeWeb

NEW YORK (GenomeWeb) – GenePOC today announced it has received CE marking for its Revogene instrument and tests for Group B Streptococcus and Clostridium difficile for marketing in Europe and other geographies that recognize the designation.

The Quebec City-based rapid molecular devices firm, which is part of Debiopharm, added that it has completed clinical trials for GBS for the US Food and Drug Administration and expects to start clinical trials for C. difficile by mid-January.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.